Study underscores promise of targeted therapies as first-line approach for patients with chronic lymphocytic leukaemia

Share :
Published: 6 Dec 2015
Views: 2236
Rating:
Save
Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano, Italy

Dr Tedeschi presents, at a press conference at ASH 2015, results from the international, randomised phase III study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naïve chronic lymphocytic leukaemia. 

Read the news story for more information.